Loading…
Oncology biotech developing and commercializing targeted cancer therapies globally, including fruquintinib (Fruzaqla).
Oncology biotech developing and commercializing targeted cancer therapies globally, including fruquintinib (Fruzaqla).
Does not sell Fruzaqla itself outside China: Takeda holds those rights, so HUTCHMED earns upfront and milestone payments, supply revenue and royalties on Takeda's sales. In China it sells some of its own drugs, and AstraZeneca pays royalties on savolitinib sales there.
In one line: A Chinese Exelixis-style oncology drug developer with global licensing deals.
Moat: narrow (IP / patents, regulatory licence). FDA/EMA-approved oncology drug with patent protection and global partner distribution.
Headquarters: Hong Kong / Shanghai, China · Founded: 2000 · Employees: 1,796
Size HUTCHMED (China) (0013.HK) is a Hong Kong Health Care company (Pharmaceuticals: Major) with a market value of $2.58B, the 374th largest of 891 Hong Kong companies the cockpit tracks. Shares closed at HK$23.16 on 6 Nov 2026.
Performance Over six months the shares gained 8.9%, against -6.5% for the median peer and -13.4% for the Hong Kong market (cap-weighted) — 6th highest of 21 in its peer set.
Growth Revenue fell 8.6% over the last twelve months (peer median +4.2%); the operating margin is -6.3% (peer median 9.1%).
Valuation It trades at 40.8× forward earnings against a peer median of 37.4× (8th cheapest of 15).
Price implies For today's price to make sense, revenue must grow about 50% a year for seven years (Req g). Recent delivered growth is +19%, so the hurdle is +31 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Next results Next results expected around 4 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | HK$4.29B | HK$4.28B | HK$4.92B | HK$6.56B | HK$3.34B |
| Revenue growth | — | -13% | -25% | +96% | — |
| Gross profit | HK$1.78B | HK$1.65B | HK$2.20B | HK$3.55B | HK$903M |
| EBITDA | -HK$160M | -HK$252M | -HK$255M | HK$200M | -HK$3.16B |
| Net income | HK$140M | HK$3.56B | HK$294M | HK$789M | -HK$2.83B |
| Free cash flow | HK$77.2M | -HK$614M | -HK$136M | HK$1.46B | -HK$2.39B |
| Capital expenditure | HK$82.2M | HK$188M | HK$140M | HK$255M | HK$287M |
| Total debt | n/a | HK$762M | HK$698M | HK$673M | HK$211M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| HUTCHMED (China) 0013.HK | $2.58B | +9% | -9% | -6% | 40.8× | 49.9% |
| Exelixis EXEL | $17.0B | +44% | +9% | 40% | 18.2× | -3.7% |
| Shanghai Junshi Biosciences 1877.HK | $4.08B | -39% | +36% | -14% | n/a | n/a |
| Innovent Biologics 1801.HK | $19.2B | -5% | +43% | 17% | 53.3× | 11.7% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 0013.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +3.7% | -1.3% | 7th highest of 21 |
| 6-month return | +8.9% | -6.5% | 6th highest of 21 |
| Distance from 52-week high | -9.5% | -25.2% | 3rd highest of 21 |
| Revenue growth (TTM) | -8.6% | +4.2% | 5th lowest of 20 |
| Operating margin | -6.3% | 9.1% | 6th lowest of 19 |
| Forward P/E | 40.8× | 37.4× | 8th cheapest of 15 |
| Growth the price implies (Req g, 7 yrs) | 49.9% | 7.3% | 2nd most demanding of 14 |
| Growth delivered (Del g) | +19.3% | +6.5% | 5th highest of 14 |
| Hurdle (Req g minus delivered) | +30.6 pp | +1.2 pp | 2nd most demanding of 14 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| HUTCHMED (China) 0013.HK | Hong Kong | $2.58B | +9% | -9% | -6% | 40.8× | 49.9% | +19.3% |
| Regencell Bioscience RGC | United States | $2.61B | -82% | n/a | n/a | n/a | n/a | n/a |
| Keymed Biosciences 2162.HK | Hong Kong | $2.48B | -6% | 0% | -73% | 18.6× | n/a | n/a |
| Neuland Laboratories NEULANDLAB.NS | India | $2.68B | +14% | +50% | 26% | 54.3× | n/a | n/a |
| Yili Chuanning Biotechnology 301301.SZ | China | $2.70B | -20% | -14% | 16% | 26.3× | 4.6% | +4.8% |
| Acrobiosystems 301080.SZ | China | $2.72B | +95% | +29% | 17% | 64.9× | 45.0% | +27.7% |
| Almirall ALM.MC | Spain | $2.74B | -2% | +24% | 8% | 30.6× | 7.3% | +6.5% |
| Kangmei Pharmaceutical 600518.SS | China | $2.77B | -22% | -6% | -7% | n/a | n/a | n/a |
| BioArctic BIOA-B.ST | Sweden | $2.78B | -3% | -46% | 22% | 53.4× | 25.7% | +100.1% |
| InSilico Medicine Cayman TopCo 3696.HK | Hong Kong | $2.80B | -43% | +153% | -7% | 100.0× | 42.1% | +22.9% |
| Vericel VCEL | United States | $2.80B | +63% | +23% | 6% | 76.2× | 50.7% | +17.3% |
| Joincare Pharmaceutical Group Industry 600380.SS | China | $2.86B | -4% | -12% | 18% | 15.6× | -13.1% | +2.4% |
| Zhejiang Hisun Pharmaceutical 600267.SS | China | $2.32B | +18% | -7% | 15% | 17.0× | -9.1% | -1.5% |
| InnoCare Pharma 688428.SS | China | $2.31B | -2% | +135% | 35% | 94.3× | -8.8% | +344.2% |
| Shandong Buchang Pharmaceuticals 603858.SS | China | $2.31B | -7% | +4% | 10% | n/a | -2.2% | -5.8% |
| Tonghua Dongbao Pharmaceutical 600867.SS | China | $2.29B | -14% | +18% | n/a | 26.2× | 1.6% | +0.3% |
| Sam Chun Dang Pharm 000250.KS | South Korea | $2.91B | -59% | +21% | 7% | n/a | n/a | n/a |
| Fujian Cosunter Pharmaceutical 300436.SZ | China | $2.26B | -35% | 0% | -47% | n/a | n/a | n/a |
| NewAmsterdam Pharma NAMS | United States | $2.26B | -51% | -26% | -900% | n/a | n/a | n/a |
| Betta Pharmaceuticals 300558.SZ | China | $3.01B | -9% | +16% | 11% | 44.2× | 25.2% | +14.0% |
| Perrigo PRGO | United States | $2.20B | +35% | -4% | 5% | 6.3× | 13.1% | +0.8% |